![](/img/cover-not-exists.png)
Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial
Bazinet, Michel, Pântea, Victor, Cebotarescu, Valentin, Cojuhari, Lilia, Jimbei, Pavlina, Albrecht, Jeffrey, Schmid, Peter, Le Gal, Frédéric, Gordien, Emmanuel, Krawczyk, Adalbert, Mijočević, Hrvoje,Language:
english
Journal:
The Lancet Gastroenterology & Hepatology
DOI:
10.1016/S2468-1253(17)30288-1
Date:
September, 2017
File:
PDF, 838 KB
english, 2017